Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Mar 27, 2024 11:04am
754 Views
Post# 35955439

Algorithms

Algorithmsappear still be manipulating this stock. We had a very brief uptick in buying which lifted us to a new 52 week high which was nice to see but our single biggest challenge is we are 100% retail play.

My question is does Arch have an investors deck? Is Arch management actively pounding the pavement with their investor deck outling the numerous reasons this is a screaming buy to Brokers, Instutional and Pension funds.

We have had a great deal of very good news and we have doubled from our 52 week low but we still still sit at $2.40 and market cap of $148, which is far below where many of our similar stage peers are. Honestly speaking we dhould be at $1B or higher at this stage with our science and past results plus new IND in the works.

Retail will not take us to the fair valued promised land, We need big buying volume to step in to move this.

2024 is shaping up to be a great year with news but the big question is when will institutional boys push their chips in and go long?
<< Previous
Bullboard Posts
Next >>